Conestat alfa(Conestat alfa) - 药物靶点：C1S x Kallikreins x MASPs_在研适应症：遗传性血管性水肿，急性缺血性卒中，急性肾损伤_专利_临床

概要

基本信息

药物类型

重组蛋白

别名

C1 Esterase Inhibitor (Recombinant)、C1 Inhibitor (Recombinant)、Complement C1 esterase inhibitor

+ [12]

靶点

C1S x Kallikreins x MASPs

作用方式

抑制剂、调节剂

作用机制

C1S抑制剂(补体C1s抑制剂)、Kallikreins调节剂(激肽释放酶调节剂)、甘露糖结合凝集素相关丝氨酸蛋白酶抑制剂

治疗领域

免疫系统疾病心血管疾病遗传病与畸形+ [4]

在研适应症

遗传性血管性水肿急性缺血性卒中急性肾损伤

非在研适应症

不稳定型心绞痛抗体介导的排斥反应新型冠状病毒感染+ [2]

原研机构

Pharming Group NV

在研机构

Pharming Group NV

Hyupjin Corp.Pharming Technologies BV

+ [1]

非在研机构-

权益机构

Pharming Group NV

NewBridge Pharmaceuticals FZ LLC

最高研发阶段批准上市

首次获批日期

欧盟 (2010-10-28),

遗传性血管性水肿

最高研发阶段(中国)-

特殊审评孤儿药 (美国)、孤儿药 (欧盟)、孤儿药 (韩国)、临床急需境外新药 (中国)

登录后查看时间轴

结构/序列

Sequence Code 9658014

来源: *****

关联

23

项与 Conestat alfa 相关的临床试验

NCT06679426

/ Not yet recruiting临床3期IIT

A Phase III, Randomized, Double-Blind, Placebo-Controlled, Multicenter Clinical Study Evaluating the Safety and Efficacy of Conestat Alfa As a Treatment for Angiotensin-Converting Enzyme-Inhibitor-Induced Angioedema

Angiotensin-converting enzyme inhibitors (ACE-Is), prescribed most often to treat hypertension, have been used extensively since the 1980s. Additional indications for their use include heart failure, diabetes mellitus, chronic kidney disease, and post-myocardial infarction. It is estimated that up to 40 million patients take ACE-Is worldwide. C1-INH is a serine protease inhibitor that is normally found in the blood. Its primary function is the regulation of the complement and contact system pathways by binding irreversibly to target proteases. It additionally inhibits the fibrinolytic, clotting, and kinin pathways.31 Patients with the hereditary forms of AE (HAE) tend to have lower quantitative or functional levels of C1-INH. This results in decreased suppression of plasma kallikrein and factor XIIa leading to cleavage of high molecular weight kininogen to form increased circulating levels of bradykinin. Bradykinin binds to bradykinin 2 receptors resulting in separation of endothelial vascular cells and extravasation of fluid manifesting clinically as angioedema. Conestat alfa (Ruconest®) is a recombinant human C1-INH that has been purified from the breast milk of genetically modified rabbits. It is a single-chain soluble glycoprotein that is made of 478 amino acids. Administering conestat alfa increases the amount of C1-INH in these patients, repleting their levels, and acting as a treatment for AE due to C1-INH deficiency. Conestat alfa has been studied on asymptomatic patients with HAE and was shown to dose-dependently increase the level of functional C1-INH. Additionally, it was shown to restore the level of the complement C4 protein, which is also decreased in these patients. Since the same pathophysiological pathway is involved in patients with ACE-I-induced AE, it is reasonable to hypothesize its effectiveness in the treatment of patients with acute attacks.

开始日期2024-12-01

申办/合作机构

University of Maryland

NCT05145283

/ Recruiting临床2期IIT

Recombinant Human C1 Esterase Inhibitor (Conestat Alfa) in the Prevention of Acute Ischemic Cerebral and Renal Events After Transcatheter Aortic Valve Implantation: a Multi-center, Randomized, Double-blind, Placebo-controlled Investigational Study (PAIR-TAVI).

The aim of this trial is to assess the safety and efficacy of conestat alfa (Ruconest®, Pharming Technologies B.V.) on renal and cerebral ischemic events in patients undergoing TAVI for severe symptomatic aortic stenosis (AS) compared to placebo.

开始日期2022-03-16

申办/合作机构

Universitätsspital Basel

[+2]

NCT04912141

/ Terminated临床2期

Conestat Alfa (a Recombinant Human C1 Esterase Inhibitor) for the Prevention of Acute Kidney Injury After Non-ST Elevation Myocardial Infarction: a Randomized, Double-blind, Placebo-controlled, Multicenter, Phase 2, Dose-finding Study

A randomized, double-blind, placebo-controlled, multi-center, phase 2 clinical study in patients with NSTEMI undergoing urgent coronary angiography. Approximately 220 patients with CKD and acute NSTEMI, who are scheduled for an urgent coronary angiography (within 72 hours after admission and/or diagnosis of NSTEMI).

开始日期2021-04-21

申办/合作机构

Pharming Technologies BV

100 项与 Conestat alfa 相关的临床结果

登录后查看更多信息

100 项与 Conestat alfa 相关的转化医学

登录后查看更多信息

100 项与 Conestat alfa 相关的专利（医药）

登录后查看更多信息

384

项与 Conestat alfa 相关的文献（医药）

2026-02-01·CLINICAL TRANSPLANTATION

Impact of C1‐Inhibitor on Renal Function and Safety Outcomes in Kidney Transplant Recipients: A Meta‐Analysis of Randomized Controlled Trials

Review

作者: Zhang, Di ; Wu, Xinzhe ; Wang, Zhigang ; Zhu, Haowei ; Zha, Boqun ; Qiu, Yang ; Shang, Wenjun ; Feng, Xinmiao

ABSTRACT:

Background:

Complement system overactivation contributes to transplanted kidney injury in both ischemia‐reperfusion and antibody‐mediated rejection, ultimately affecting post‐transplant renal function. C1 esterase inhibitor (C1‐INH) may reduce complement‐mediated injury, yet its effects on renal function and safety outcomes remain uncertain in randomized trials.

Methods:

Four RCTs were included, all focusing on the use of C1‐INH in kidney transplant recipients, comparing it with control groups receiving saline. The studies were evaluated for methodological quality using the Jadad scoring system and the Cochrane Risk of Bias tool. Meta‐analysis was performed using RevMan software, assessing outcomes such as renal function (eGFR), AMR incidence, and SAE occurrences.

Results:

This study included four randomized controlled trials encompassing 148 kidney transplant recipients. The findings suggest that treatment with C1‐INH may be associated with an improvement in renal function, as reflected by eGFR. No statistically significant difference was observed in the incidence of delayed graft function or antibody‐mediated rejection between the treatment and control groups. The overall incidence of serious adverse events was comparable between groups, with no significant differences detected in infection‐related, renal, cardiovascular, or gastrointestinal events.

Conclusion:

The use of C1‐INH may be associated with improved graft renal function following kidney transplantation. However, no significant benefit was observed with respect to delayed graft function or antibody‐mediated rejection. The available evidence suggests an acceptable safety profile for C1‐INH in this setting. Nevertheless, given the clinical heterogeneity of the included studies and the limited cumulative sample size, these findings should be interpreted as preliminary. Larger, well‐designed randomized controlled trials are required to further clarify the therapeutic role of C1‐INH in kidney transplantation.

2025-11-01·World Allergy Organization Journal

C1 esterase inhibitor (C1–INH) response as a supportive diagnostic criterion for patients with suspected hereditary angioedema with normal C1–INH

Article

作者: Patel, Maunish ; Fatteh, Shahnaz ; Jones, Douglas H ; Rivera, Ralph ; Lim, Lily M ; Rumbyrt, Jeffrey ; Smith, Andrew M ; Chu, Teresa ; Kanarek, Henry J ; Memmott, Heidi ; Kashkin, Jay M ; Hussain, Yusaf

Diagnosis of hereditary angioedema (HAE) with normal C1INH level (HAE-nl-C1INH) is based on several criteria, including either an associated genetic variant identified or family history of recurrent angioedema plus lack of high-dose antihistamine response. A rapid, durable response to bradykinin-targeted medication is considered supportive, and this study aimed to evaluate the use of recombinant human C1 esterase inhibitor (rhC1-INH) in this regard. A retrospective medical records review was conducted for angioedema/HAE codes. Thirty-one patients with HAE-nl-C1INH were identified (female, 87.1%; mean age, 46.2 years; range, 16-74 years). All patients had experienced recurrent angioedema, with documentation of antihistamine and/or mast cell-targeted therapy ineffectiveness and normal/near-normal laboratory data. Genetic testing (n = 9) found no known pathogenic variants of HAE. Diagnosis of HAE-nl-C1INH was confirmed in the 31 patients via a favorable response after intravenous rhC1-INH (weight-based; maximum, 4200 U) during an angioedema attack. Only 30.0% (9/30) of patients with documented information had been aware of a family history of recurrent angioedema/HAE. In conclusion, reliance on a family history of recurrent angioedema as a diagnostic criterion may delay accurate diagnosis and access to effective treatment. These results support that responsiveness to C1-INH replacement therapy may also be a useful supportive diagnostic criterion for HAE-nl-C1INH.

2025-11-01·World Allergy Organization Journal

Hereditary angioedema: A national investigation of associated comorbidities and surgical procedures

Article

作者: Szilágyi, Tamás ; Andrási, Noémi ; Voloncs-Mindszenthy, Lili ; Farkas, Henriette ; Horváth, Hanga Réka

Background:

Hereditary angioedema due to C1 inhibitor deficiency (HAE-C1INH) is characterized by sudden subcutaneous and/or submucosal angioedema attacks. C1 inhibitor is a serine protease inhibitor that regulates several enzyme cascade systems. The absence of this control raises concerns about the potential development of comorbidities.

Objective:

We aimed to investigate the comorbidities present in the Hungarian HAE-C1INH patient population and to examine the surgical procedures performed on these patients. Additionally, we sought to compare our results to those of the Hungarian general population.

Methods:

Demographical, clinical, laboratory, and radiographic data of all 178 adult HAE-C1INH patients followed up at the Hungarian Angioedema Center of Reference and Excellence were used to examine comorbidities and surgical procedures. Information about the general Hungarian population was extracted from national and European statistical databases and individual articles.

Results:

At least 1 comorbidity was present in 159 of our patients. From the observed 51 diseases, headache (58%), hypercholesterolemia (52%), hypertension (30%), and liver diseases (26%) were the most prevalent. Hypercholesterolemia and depression/anxiety were at least 3 times more common in the HAE-C1INH population as compared to the Hungarian general population. Tonsillectomy was performed 32, appendectomy 11, and inguinal hernioplasty 2 times more often before the diagnosis of HAE-C1INH was established. Every surgical procedure was more prevalent in the HAE-C1INH population.

Conclusion:

Regular, targeted screening is indispensable for the prevention and timely diagnosis of certain diseases found in higher prevalence in the HAE-C1INH population. The early identification and adequate treatment of angioedema attacks help prevent avoidable surgical interventions.

60

项与 Conestat alfa 相关的新闻（医药）

2026-02-02

·FiercePharma

With FDA rejections, Aquestive's shares go up, while Pharming's go down

The FDA issued complete response letters to Aquestive Therapeutics and Pharming in recent days, resulting in vastly different reactions from the market. While Aquestive's share price increased, Pharming's dropped. The FDA issued complete response letters (CRLs) to two companies in recent days, resulting in vastly different reactions from the market.The U.S. regulator rejected Pharming’s bid to gain an expansion for Joenja to treat patients ages 4 to 11 with activated phosphoinositide 3-kinase delta syndrome (APDS), a rare immunodeficiency. With the thumbs down, Pharming’s share price tumbled by 16% on Monday.Meanwhile, the FDA also swatted away Aquestive Therapeutics’ new drug application for Anaphylm sublingual film for the treatment of Type 1 allergic reactions, including anaphylaxis, in patients weighing at least 30 kg (66 pounds). But with the red light, Aquestive’s share price increased by 35%.The reason for the optimism on Anaphylm? The FDA’s concerns with the rescue treatment were limited to its packaging, administration and labeling guidance.“While it is unfortunate to have received a CRL, we believe that, with the clarity we now have from the FDA, we have made significant progress toward approval,” Dan Barber, the CEO of Aquestive, said in a release.The regulator cited difficulties in opening Anaphylm’s pouch and the potential for incorrect film placement, which “the FDA believes could cause significant safety issues in the setting of anaphylaxis,” Aquestive said in a release.“This opening is the one we use with multiple other products that are on the market and one product that’s been on the market for 15 years,” Barber said during a conference call on Monday morning. “It’s a bit of a head scratcher, but we’ll do the work that the FDA has requested.” Aquestive said it has already modified the pouch opening, its instructions for the drug's use and the labeling on its carton. The company will also conduct a new human factors validation study and plans to address potential tolerability issues with its resubmission, which could happen as early as the third quarter, it added.As a needle-free, oral epinephrine option, Anaphylm has been pegged as a potential blockbuster and a game-changer for the New Jersey-based company, which projected in November that its 2025 revenue would come in at between $44 million and $50 million.The CRL does not affect submissions for approval of the treatment in Europe and Canada, which are still on track by the end of this year, Aquestive said. Pharming rejectionIn the CRL the FDA sent to Pharming, the agency cited the potential for “underexposure” in lower-weight patients and has requested additional pediatric pharmacokinetic (PK) data, the company said. The FDA wants to reassess the proposed pediatric doses and confirm that children in the lower-weight dose groups can achieve exposure levels comparable to the approved regimen. The letter also identified an issue with one of the analytical methods used for production batch testing.“While we are disappointed in the FDA’s response, we remain dedicated to making Joenja available to pediatric patients aged 4-11 with APDS,” Fabrice Chouraqui, the CEO of the Netherlands-based company, said in a release. “We are going to work closely with the FDA to provide the necessary information and determine the best and most effective path forward.”The company said it believes it can address the PK and batch testing methodology issues and will request a Type A meeting with the FDA. Analysts from Jefferies noted that “importantly,” the CRL did not reflect any efficacy concerns, indicating that the drug will likely eventually gain approval for the age group. Jefferies added that a third-quarter approval would be a “best-case” scenario at this stage.More information could be available during the company’s investor presentation on Tuesday. Last month, Pharming reported (PDF) preliminary 2025 revenues of $376 million, up 27% from 2024. Through three quarters, Joenja—which was approved in 2023—had produced sales of $38 million, with $15 million coming in the third quarter.The big seller for Pharming is Ruconest, which generated sales of $231 million through the first nine months of 2025. The treatment was approved in 2014 for hereditary angioedema.

上市批准

2026-02-02

·EndPoints

Pharming’s immunodeficiency drug gets CRL for use in younger patients

The FDA has issued a complete response letter to Pharming, rejecting its attempt to expand the approval of its drug for a rare form of immunodeficiency into younger patients. Joenja was approved in 2023 for a disorder called activated phosphoinositide 3-kinase delta syndrome (APDS) in patients aged 12 and up. On Sunday, the company said the regulator declined to approve the pill’s use in patients aged 4 to 11. Pharming’s Amsterdam-listed shares fell 15% in early trading on Monday. Growing Joenja’s sales is important for Pharming. Analysts expect revenues from its only other product, the hereditary angioedema therapy Ruconest, to fall starting this year, as some patients switch to KalVista’s Ekterly . According to Pharming, the FDA asked for more pediatric pharmacokinetic data due to concerns that lighter patients could be underexposed to the drug. The regulator wants to confirm that children in the lower-weight dose groups can be exposed to similar levels of Joenja as adult and adolescent patients. The approved dose for older patients is two 70 mg pills a day. Patients must weigh at least 45 kg to get the drug. The CRL also identified a problem with one of the methods used to test batches of the drug, and again the FDA requested additional data and clarification on this point. Pharming said it could address the issues raised in the letter and would seek a meeting with the FDA to discuss resubmission. Jefferies analysts wrote in a Monday note that they expect Joenja to be approved in the wider population “eventually,” as the letter did not take issue with the drug’s efficacy. They believe that expanded approval in the third quarter of 2026 could be the best-case scenario, with approval later in the year also a possibility, “assuming it will not take more than a couple of months to generate the required data.” APDS is caused by mutations in one of two genes, known as PIK3CD or PIK3R1, which regulate the maturation of white blood cells, particularly B cells and T cells. These cause hyperactivity of PI3 kinase delta, leading to proliferation of immature B and T cells, which can’t fight infections. Joenja is a small molecule that blocks the production of PI3 kinase delta, allowing immune cells to mature properly. The disorder is ultra-rare, affecting only one or two people in every million. In the US, Joenja costs around $50,000 for a month’s supply. The drug could gain approval in Europe and Japan this year. Phase 2 trials assessing it in patients with other primary immunodeficiencies due to immune dysregulation are also expected to report this year.

上市批准免疫疗法临床2期加速审批

2026-01-08

·pharming.com

Pharming Group reports preliminary 2025 revenues and announces Investor Day

Total 2025 revenues are estimated to be approximately US$376 million*, exceeding the upwardly revised guidance range of US$365 to US$375 million provided in November 2025 and representing approximately 27% growth versus 2024. This strong performance reflects continued growth of RUCONEST® and rising demand for Joenja®, driven primarily by patient uptake in the U.S. and supported by ongoing geographic expansion. Full-year 2025 operating expenses are expected to be within the previously communicated range of US$304 to US$308 million, underscoring our commitment to cost discipline. Looking ahead, we anticipate sustained revenue growth and continued advancement of our clinical pipeline in 2026. We plan to report complete fourth quarter and full year 2025 financial results on March 12, 2026. The Investor Day agenda will include a comprehensive update on our advancing pipeline, including leniolisib in Phase II proof of concept clinical trials for primary immunodeficiencies (PIDs) with immune dysregulation, including Common Variable Immunodeficiency (CVID) with immune dysregulation, as well as KL1333 in a pivotal clinical study (FALCON) for mitochondrial DNA (mtDNA)-driven mitochondrial disease. We will also present our 2026 financial guidance, highlighting anticipated revenue drivers and operating expense expectations. The program will feature presentations from leading clinical experts: Jocelyn Farmer, MD, PhD, Lahey Hospital & Medical Center — an internationally recognized authority on immune dysregulation and CVID Amel Karaa, MD, Massachusetts General Hospital, Harvard Medical School — an internationally recognized authority on mitochondrial medicine These key opinion leaders will discuss the evolving understanding of immune dysregulation in PIDs and the unmet need in mtDNA‑related mitochondrial disease, providing important clinical context for our development programs. Fabrice Chouraqui, Chief Executive Officer of Pharming, commented: “We delivered a strong year in 2025, driven by robust demand for our commercial assets and renewed financial discipline. RUCONEST® continued to grow in an increasingly competitive environment, while Joenja® uptake accelerated with rising U.S. patient demand and international expansion. As we enter 2026, we remain focused on advancing our clinical programs for additional PIDs with immune dysregulation and primary mitochondrial disease, while supporting continued growth of our commercial portfolio to drive long-term value creation. We look forward to providing a deeper update on these initiatives and sharing our 2026 financial outlook at our upcoming Investor Day.” Additional details for the Investor Day, including registration information, will be made available on our website in the coming weeks. * Preliminary, unaudited revenues. Final results may differ from the estimates provided in this release and will be reported in the Company’s financial results for the fourth quarter and full year 2025, to be published in March 2026.

临床2期财报免疫疗法

100 项与 Conestat alfa 相关的药物交易

登录后查看更多信息

外链

KEGG	Wiki	ATC	Drug Bank
D10845	Conestat alfa	B06AC04	DB09228

研发状态

批准上市

10 条最早获批的记录,

登录

后查看更多信息

适应症	国家/地区	公司	日期
遗传性血管性水肿	欧盟	Pharming Group NV	2010-10-28
遗传性血管性水肿	冰岛	Pharming Group NV	2010-10-28
遗传性血管性水肿	列支敦士登	Pharming Group NV	2010-10-28
遗传性血管性水肿	挪威	Pharming Group NV	2010-10-28

未上市

10 条进展最快的记录,

登录

后查看更多信息

适应症	最高研发状态	国家/地区	公司	日期
急性缺血性卒中	临床2期	瑞士	Pharming Technologies BV	2022-03-16
不稳定型心绞痛	临床2期	瑞士	Pharming Technologies BV	2021-04-21
非ST段抬高型心肌梗死	临床2期	瑞士	Pharming Technologies BV	2021-04-21
新型冠状病毒感染	临床2期	巴西	Pharming Technologies BV	2020-08-06
新型冠状病毒感染	临床2期	墨西哥	Pharming Technologies BV	2020-08-06
新型冠状病毒感染	临床2期	瑞士	Pharming Technologies BV	2020-08-06
急性肾损伤	临床2期	瑞士	Pharming Technologies BV	2017-01-01
抗体介导的排斥反应	临床2期	美国	Pharming Technologies BV	2010-12-01
器官移植排斥	临床2期	美国	Pharming Technologies BV	2010-12-01

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


NCT01359969 (CTgov)	临床2期	遗传性血管性水肿	57	rhC1INH	鑰積鬱壓蓋廠蓋網蓋積(襯窪鏇壓鏇範壓構襯鑰) = 壓齋膚築築衊鏇構鬱衊壓糧繭網鏇選壓鹹糧積 (壓廠鏇糧餘廠範繭蓋築, 艱範簾構鬱鑰膚遞鏇襯 ~ 顧繭淵艱壓糧齋鏇鹹願) 更多	-	2024-03-29
NCT04530136 (CTgov)	临床2期	新型冠状病毒感染	38	Ruconest (Ruconest)	餘積築齋齋壓選選鹽構 = 簾憲簾網壓襯鏇壓淵醖蓋顧網糧壓鬱觸壓選獵 (鹹餘築簾製積積獵襯顧, 蓋積醖夢積觸醖齋製積 ~ 廠齋鹽簾觸願範襯遞壓) 更多	-	2024-02-16
				Ruconest (Standard of Care)	餘積築齋齋壓選選鹽構 = 淵繭憲襯鬱艱顧鏇簾積蓋顧網糧壓鬱觸壓選獵 (鹹餘築簾製積積獵襯顧, 壓製淵廠餘醖膚醖鏇簾 ~ 夢構襯範鑰繭鹽選簾膚) 更多
NCT02869347 (PROTECT, ERA2019)	临床2期	肾脏疾病 urinary neutrophil gelatinase-associated lipocalin (NGAL) \| serum C1 inhibitor levels \| cystatin C	77	Conestat alfa	鏇觸鏇廠範憲遞衊築繭(衊衊觸遞網獵積築構積) = 鏇鹹範獵網繭襯艱齋夢繭憲遞鏇積顧窪網鬱鏇 (範鹽襯鹽蓋鑰獵鏇製鑰 ) 更多	积极	2019-06-13
				Placebo	鏇觸鏇廠範憲遞衊築繭(衊衊觸遞網獵積築構積) = 獵淵醖窪選膚鑰窪鹽壓繭憲遞鏇積顧窪網鬱鏇 (範鹽襯鹽蓋鑰獵鏇製鑰 ) 更多
NCT02247739 (CTgov)	临床2期	遗传性血管性水肿	32	Recombinant human C1 inhibitor (rhC1INH Twice Weekly)	糧簾膚壓艱鑰廠築壓鹽(夢廠鏇構壓範醖網窪簾) = 衊餘鬱選遞艱糧築齋鹽願餘夢選壓淵選艱顧範 (網築糧願鬱壓夢艱鏇壓, 鏇齋襯範願願蓋憲衊齋 ~ 艱鹽網鏇廠範選鹹觸觸) 更多	-	2017-12-08
				Recombinant human C1 inhibitor (rhC1INH Once Weekly)	糧簾膚壓艱鑰廠築壓鹽(夢廠鏇構壓範醖網窪簾) = 鏇餘積餘顧鹽艱艱淵簾願餘夢選壓淵選艱顧範 (網築糧願鬱壓夢艱鏇壓, 窪淵憲築醖膚壓積顧遞 ~ 夢夢襯襯艱襯鏇艱築艱) 更多
NCT01188564 (CTgov)	临床3期	遗传性血管性水肿	75	rhC1INH (rhC1INH)	餘廠簾築艱選膚願顧鏇(鹹糧餘鹽網壓鏇獵網簾) = 艱選壓網選構壓遞齋構糧廠壓願獵築築繭糧齋 (鏇鏇齋蓋膚積膚築鹹齋, 淵夢壓製範遞蓋遞醖醖 ~ 糧鹽選製願窪廠窪襯艱) 更多	-	2015-08-07
				Placebo (Saline) (Placebo (Saline))	餘廠簾築艱選膚願顧鏇(鹹糧餘鹽網壓鏇獵網簾) = 範簾衊選願構廠糧遞願糧廠壓願獵築築繭糧齋 (鏇鏇齋蓋膚積膚築鹹齋, 夢鏇鏇築衊壓繭鹹選範 ~ 膚膚壓窪積鏇網壓鹹壓) 更多
NCT01188564 (Pubmed \| Ann Allergy Asthma Immunol) 人工标引	临床3期	遗传性血管性水肿	75	rhC1INH	願壓遞醖簾艱構築鹽顧(鏇獵淵顧膚獵廠糧鹽選) = 鹹繭窪構製選醖憲觸醖獵襯蓋餘廠製齋糧艱艱 (製膚膚願鏇願醖願築衊, 61 ~ 150) 更多	积极	2014-02-01
				Placebo	願壓遞醖簾艱構築鹽顧(鏇獵淵顧膚獵廠糧鹽選) = 糧壓築鏇憲選鏇襯鑰積獵襯蓋餘廠製齋糧艱艱 (製膚膚願鏇願醖願築衊, 93 ~ NE) 更多
NCT00851409 (OPERA, CTgov)	临床2期	遗传性血管性水肿	25	Recombinant Human C1 Inhibitor	獵願觸積獵艱艱壓蓋願(艱觸製夢簾壓顧鑰顧構) = 蓋壓鬱蓋衊餘顧構蓋窪壓選蓋膚淵遞壓觸鹹鏇 (繭簾醖願衊餘網憲齋餘, 壓遞壓鹹襯鏇簾艱築襯 ~ 鹹構築構積憲簾膚顧鹽) 更多	-	2013-01-31
NCT00262301 (CTgov)	临床3期	遗传性血管性水肿	75	recombinant human C1 inhibitor (100 IU/kg "rhC1INH")	觸艱觸壓膚夢餘膚淵齋(廠蓋壓構餘襯顧築築選) = 繭繭醖餘繭簾範齋鬱鑰鑰願網網積選遞醖遞艱 (選鏇遞積鏇憲積簾廠鏇, 膚膚積簾築壓繭襯壓選 ~ 蓋窪構選壓鑰積鑰鑰廠) 更多	-	2012-08-30
				Placebo (Saline)	觸艱觸壓膚夢餘膚淵齋(廠蓋壓構餘襯顧築築選) = 築遞繭製淵夢築鏇構鏇鑰願網網積選遞醖遞艱 (選鏇遞積鏇憲積簾廠鏇, 窪窪壓構願齋構築衊餘 ~ 蓋製鹽夢廠簾膚獵廠鏇) 更多